Amanda Mogul is originally from Albany, N.Y., and received her PharmD from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed a PGY-1 residency at the Samuel S. Stratton Veterans Affairs Medical Center in Albany, and a PGY-2 Ambulatory Care Residency at Rhode Island Hospital in Providence, R.I. She is a Board Certified Ambulatory Care Pharmacist (BCACP).
Mogul practices as an ambulatory care pharmacist at Lourdes Hospital internal medicine clinic in Vestal, N.Y, and is a New York State Certified Drug Therapy Management (CDTM) pharmacist. She is actively involved in the New York State Council of Health-system Pharmacists (NYSCHP), currently serving as a co-advisor of the student chapter at the Binghamton SOPPS. She also serves on the board of directors and grassroots advocacy committee for NYSCHP-Southern Tier and on the Scholarly Activity Committee for the American College of Clinical Pharmacy’s (ACCP) Ambulatory Care PRN.
Zullo AR, Mogul A, Corsi K, Shah NR, Lee SJ, Rudolph JL, et al. Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e004942.
Mogul A, Corsi K, McAuliffe L. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. Ann Pharmacother. 2019 Mar 24;1060028019839650.
- PharmD, State University of New York at Buffalo
- Diabetes Management
- Prevention of cardiovascular disease
- Primary Care
- Transitions of Care